Estradiol, Progesterone and Endometrial Thickness in Frozen Euploid Embryo Transfer
1 other identifier
observational
299
1 country
1
Brief Summary
The development and improvement in Preimplantation genetic diagnosis/screening (PGS) in association with the efficacy and security of vitrification and trophectoderm biopsy, more efficient stimulation schemes and laboratory improvements in culture and embryo selection have contributed to high success of the assisted reproductive technologies(ART). Transferring an euploid embryo avoids one of the main reasons of miscarriage and implantation failure ( Rubio et al, 22016) and overcomes one of the most important confounding factors. Usually, the transfer of euploid embryos is performed under standard hormone replacement therapy (HRT) and are referred to as FET-PGS cycles( Frozen embryo transfer). The study of FET-PGS cycles with the transfer of a single euploid blastocyst is the best model for evaluation of the impact of the endometrial preparation . Among factors influencing FET outcomes, patient's age, endometrial preparation, endometrium thickness, endometrial pattern, number and quality of embryos transferred , difficulty at ET, recently P4 have received more attention . The importance of Progesterone (P4) in embryo implantation has been widely studied. P4 plays an important role in endometrial gland formation, embryonic implantation and pregnancy maintenance, both in natural and artificial cycles.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2018
CompletedFirst Submitted
Initial submission to the registry
January 4, 2018
CompletedFirst Posted
Study publicly available on registry
January 10, 2018
CompletedFebruary 28, 2018
February 1, 2018
3.9 years
January 4, 2018
February 27, 2018
Conditions
Outcome Measures
Primary Outcomes (3)
Live birth rate
Ten months after transfer procedure
Miscarriage rate
Miscarriage was defined as a loss following a positive pregnancy test and/or detectable Gestational sac
Any pregnancy loss before week 20
Pregnancy rate
6 weeks after transfer procedure
Interventions
Estradiol level measured at previous day of embryo transfer procedure
Progesterone level measured at previous day of embryo transfer procedure
Endometrial thickness measured at previous day of embryo transfer procedure
Eligibility Criteria
Women who underwent blastocyst trophectoderm biopsy and PGS and frozen-thawed embryo transfers(PGS-FET) performed after the In Vitro Fertilization (IVF) . PGS was implemented as 46-chromosome screening, using array comparative genomic hybridization (aCGH) from Day 5 trophectoderm biopsy. Whole-genome amplification, processing and analyses were performed using the kits, software and protocols for array Comparative Genomic Hybridisation (aCGH) analysis provided by the manufacturer (SurePlex® DNA Amplification System, 24Sure® Microarray Pack, Bluefuse®, Illlumina®).
You may qualify if:
- Frozen embryo transfer (FET) of at least one single euploid embryo.
- Estradiol \> 75pg/ml.
- Progesterone \> 4 ng/ml.
- Endometrial thickness between 6 mm and 18 mm.
You may not qualify if:
- Patients with FET of no diagnostic or mosaic embryos, or known uterine abnormality were excluded.
- Natura cycle protocol.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Fundacion Dexeuslead
Study Sites (1)
Department of Obstetrics, Gynaecology and Reproduction Instituto Universitario Dexeus
Barcelona, 08028, Spain
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CROSSOVER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of Reproductive Medicine Service
Study Record Dates
First Submitted
January 4, 2018
First Posted
January 10, 2018
Study Start
January 1, 2014
Primary Completion
December 1, 2017
Study Completion
January 1, 2018
Last Updated
February 28, 2018
Record last verified: 2018-02
Data Sharing
- IPD Sharing
- Will not share